A categoryof one.
The only manufacturer of autologous fat-transfer aesthetic products.
A market worth$1.1 to 2.5 billion,with no product in it.
Every major category in aesthetics has a company that makes the product. Autologous fat transfer, the largest natural volume procedure, has none: the product is the patient's own tissue, so it is delivered entirely as surgery.
Every category has a maker. Except one.
Step 1:
Less than one gram.
A needle biopsy captures the patient's own fat. No liposuction, no operating room.
Step 2:
A thousandfold.
The patient's own cells, expanded roughly 1000× into living, manufactured tissue.
Step 3:
ETB-001.
One manufactured biologic: the patient's own living tissue, in a syringe.
Face
Breast
Body
HandStep 5:
$1.1 to 2.5 billion
One platform across every indication, into a U.S. fat-transfer market delivered until now only as surgery.
Step 4:
The only manufactured fat transfer.
One autologous platform, across every indication.
Surgery becomes an office injectable.
Same physician, same day, four to eight times the throughput. And a channel of roughly 12,000 U.S. dermatologists, who perform a third of all aesthetic procedures but zero fat transfer, opens for the first time.
The moat is biology. The timing is now.
The moat is biology
A filler company cannot reformulate its way into autologous tissue. A device company cannot engineer its way in. The category has one key.
One harvest, two products
Volume and structure from the same sample: adipose tissue and natural collagen. No synthetic material anywhere in the product.
A regulatory head start
A 351 biologic pathway with 12 years of marketing exclusivity on BLA approval, backed by two issued patents. A follower starts from zero.
The timing is now
GLP-1 weight loss is stripping soft-tissue volume at population scale, and patients increasingly want their own tissue. The category compounds 13 to 16.5% a year through 2032.
Funded, published, and moving toward the clinic.
$10M
Department of Defense grant
26-wk
NHP safety study complete
1000×
Expansion from <1g of tissue
2
Patents issued
12 yr
Marketing exclusivity on BLA
400+
Citations across top journals
Backed by an exclusive University of Massachusetts collaboration in adipose stem cell biology. Lead program ETB-001 advances across four indications, hand first, then facial, breast, and body.
Built by people who have taken products through the FDA. Repeatedly.
Janet DeLeon
Co-Founder, President & CEO
Aventis · Cypress Pharmaceutical
Robert Lewis
Co-Founder, Chairman
Teva · Sigma · Cypress Pharmaceutical
Missy Clifton, MD
Co-Founder, Chief Medical Officer
Founding partner, Premier Dermatology & Aesthetics
Tim Dugan
Co-Founder, Chief Clinical Officer
Burke Pharmaceutical Research · 200+ derm trials
100+ FDA approvals combined, across devices, biologics, and cell therapy.
The category is open. There is one key.
Etienna is raising a Series Seed of $5 to 10 million to complete IND-enabling studies and meet with the FDA: the first autologous fat-transfer product, and the only entry into a market delivered until now entirely as surgery.